[Modern coagulation management reduces the transfusion rate of allogenic blood products]

Anasthesiol Intensivmed Notfallmed Schmerzther. 2012 Jun;47(6):418-24; quiz 425. doi: 10.1055/s-0032-1316484. Epub 2012 Jun 28.
[Article in German]

Abstract

Evaluating the patient's individual bleeding history with a standardized questionnaire, using "point-of-care" - methods for coagulation analyses and providing autologous transfusion techniques are preconditions of a modern coagulation management. Therapy of coagulopathic patients should be based on structured hemotherapy algorithms. Surgical haemostasis and the maintenance of the basic conditions for haemostasis are elementary requirements for an effective therapy. In cases of diffuse bleeding, early antifibrinolytic therapy should be considered. Coagulation factor deficiencies should be corrected "goal-directed" using coagulation factor concentrates. Transfusion of fresh frozen plasma is only indicated in the clinical setting of massive transfusions. DDAVP and transfusion of platelet concentrates are options to optimize primary haemostasis. In cases of on-going bleeding, recombinant activated coagulation factor VII represents an option for "ultima-ratio" therapy.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Antifibrinolytic Agents / therapeutic use
  • Blood Coagulation Disorders / blood
  • Blood Coagulation Disorders / diagnosis
  • Blood Coagulation Disorders / drug therapy
  • Blood Coagulation Tests
  • Blood Coagulation*
  • Blood Loss, Surgical / prevention & control
  • Blood Transfusion / mortality
  • Coagulation Protein Disorders / therapy
  • Deamino Arginine Vasopressin / therapeutic use
  • Hemostasis
  • Humans
  • Hypotension, Controlled
  • Intraoperative Care
  • Plasma
  • Platelet Transfusion
  • Point-of-Care Systems
  • Transfusion Reaction*

Substances

  • Antifibrinolytic Agents
  • Deamino Arginine Vasopressin